Enzolytics (OTC: ENZC) and Creatd (OTC: CRTD): Exploring Biotech Innovation Through Strategic Transformation

A groundbreaking biotech firm's lifesaving research was nearly derailed by corporate turmoil until Creatd stepped in, transforming Enzolytics from a troubled company into a potential powerhouse in the fight against HIV, cancer, and immune disorders through innovative antibody therapies and AI-driven drug discovery.

In the world of biotechnology, scientific breakthroughs don’t always translate to success. Cutting-edge research can be overshadowed by financial missteps, regulatory pitfalls, or the ruthless nature of public markets. This is precisely the crossroads where Enzolytics, Inc. (OTC: ENZC) and Chief Science Officer Harry Zhabilov found themselves—on the verge of pioneering transformative monoclonal antibody therapies while simultaneously grappling with corporate turmoil.

Enter Creatd, Inc. (OTC: CRTD), a company built for moments like these. Under the leadership of CEO Jeremy Frommer, Creatd has stepped in not just as a financial stabilizer but as a strategic partner poised to realign Enzolytics’ business with its scientific ambitions. More than a mere investment, this collaboration signals a complete restructuring, ensuring that Enzolytics’ groundbreaking work in immunotherapy and AI-driven drug discovery takes center stage.

The Science Behind Enzolytics: A Revolution in Biotech

Under the guidance of Harry Zhabilov, the biotechnology firm dedicated to developing therapeutics for some of the most challenging diseases, including HIV, cancer, and immune-related disorders. Its research is driven by two key innovations.

The first is monoclonal antibody therapy. Enzolytics has developed proprietary methodologies for creating broadly neutralizing antibodies that target conserved sites on viruses. Unlike traditional treatments that struggle against viral mutations, this approach focuses on unchanging viral structures, offering a potentially groundbreaking solution for diseases that have long defied effective treatment.

The second is artificial intelligence-driven drug discovery. By leveraging AI, Enzolytics accelerates the identification of therapeutic targets and refines the development process. This integration of machine learning enhances precision medicine while reducing both the cost and time required to bring new therapies to market.

Despite these scientific advancements, Enzolytics faced major challenges—not in the lab, but in the boardroom. The SEC’s allegations of stock manipulation and mismanagement against key figures within the company threatened to derail its progress. Without a fundamental restructuring, its promising technology risked never reaching the patients who need it most.

Creatd’s Strategic Play: More Than Just a Rescue Mission

Creatd’s involvement with Enzolytics isn’t just about salvaging a struggling company; it’s about unlocking hidden potential. Through its broader Project 100 initiative, Creatd specializes in identifying undervalued microcap assets—companies with game-changing products but weak business structures that prevent them from capitalizing on their innovations. Enzolytics fits this mold perfectly.

Jeremy Frommer, now an executive board member at Enzolytics, has made it clear that his role is to bring stability and ensure that the company’s scientific vision is no longer overshadowed by past mismanagement. His strategy includes strengthening the balance sheet to address financial weaknesses, implementing leadership changes and stricter compliance measures to overhaul corporate governance, and supporting immediate revenue initiatives such as launching innovative food supplements with medical applications to provide near-term financial stability. Additionally, he plans to align the company with strategic investors who share its long-term vision.

“We’re here to ensure that Harry’s work doesn’t just remain in the lab but becomes a global force in healthcare,” Frommer stated. “The days of bad actors exploiting this company for personal gain are over. Our focus is on rebuilding, repositioning, and ensuring that science takes the lead.”

The Road Ahead: A New Era for Enzolytics

With Frommer’s guidance, Enzolytics is already making strides toward its transformation. The company has joined CEOBLOC, an advocacy group for emerging growth companies, and is in the process of restructuring its stock with an assigned new CUSIP. Additionally, it has submitted documentation to FINRA for approval of a reverse split—a critical step toward uplisting and regaining credibility in the public markets.

Harry Zhabilov, Enzolytics’ Chief Science Officer and the visionary behind its therapeutic developments, sees this partnership as a turning point. “Creatd’s support allows us to focus on what we do best: advancing science. With their strategic backing, we can bring our research to market faster and more effectively than ever before.”

A Model for Future Success

The Enzolytics-Creatd partnership exemplifies the kind of strategic intervention that can turn struggling biotech firms into powerhouses. By blending scientific excellence with disciplined business leadership, this collaboration sets a precedent for how undervalued innovation can be revitalized.

Frommer sums it up best: “This is exactly what Creatd was built for—taking overlooked companies with incredible potential and giving them the structure they need to thrive. With Enzolytics, we’re not just fixing a business; we’re fueling a scientific revolution.”

As Enzolytics regains its footing, the biotech world will be watching. With the right leadership and a renewed focus, it has the potential to not only fulfill its mission but redefine the future of disease treatment.